Effect of a WeChat Platform-based Management Intervention on Blood Pressure Control: A Randomized Clinical Trial.
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 436
- Primary Endpoint
- Proportion with controlled blood pressure at 12 months (defined by ambulatory blood pressure monitoring )
Study Overview
Brief Summary
WeChat is the largest and most popular social media platform in China, In this study, investigators will evaluate the use of management program delivered via WeChat platform in patients with hypertension.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients aged ≥ 18 years with confirmed diagnosis of hypertension
- •Office systolic blood pressure (SBP)≥140 mmHg and/or diastolic blood pressure (DBP)≥90 mmHg, or ambulatory blood pressure monitoring (ABPM) indicating 24- hour SBP ≥130 mmHg and/or DBP ≥80 mmHg and/or daytime SBP ≥135 mmHg and/or DBP ≥85 mmHg and/or nocturnal SBP ≥120 mmHg and/or DBP ≥70 mmHg.
- •Patients have smart phone and often use WeChat to communicate with others (including written interaction)
- •Patients are willing and able to give informed consent for participation in the trial
Exclusion Criteria
- •Secondary hypertension
- •Hypertensive emergency: defined as severe elevations in BP (SBP ≥180 mmHg and/or DBP≥120mmHg) associated with evidence of new or worsening target organ damage, including hypertensive encephalopathy, intracranial hemorrhage, cerebral hemorrhage, subarachnoid hemorrhage, cerebral infarction, heart failure, acute coronary syndrome (unstable angina, acute myocardial infarction), aortic dissection, perioperative hypertension, preeclampsia, and eclampsia
- •Refractory hypertension: defined as failure to control BP despite lifestyle changes and use of at least 5 antihypertensive agents of different classes, including a thiazide-type diuretic and a mineralocorticoid receptor antagonist
- •Pregnancy or lactation or having pregnancy plan during the study period
- •Life expectancy less than 1 year
- •Participation in another clinical study or clinical trial in the 3 months prior to the confirmation of eligibility or current user of WeChat platform provided by hypertension center of the first affiliated hospital of Wenzhou medical university
Arms & Interventions
Intervention
The intervention group will be enrolled into WeChat platform. Participants will receive health education materials, monitor blood pressure at home and sent the blood pressure record to the platform and consult doctors online via platform.
Intervention: WeChat platform group (Other)
Control
Control group will receive usual care and follow up in hospitals and community health centers.
Outcomes
Primary Outcomes
Proportion with controlled blood pressure at 12 months (defined by ambulatory blood pressure monitoring )
Time Frame: 12 months
mean 24-hour ambulatory blood pressure monitoring (ABPM) \<130/80 mmHg, day time blood pressure \<135/85 mmHg, and nocturnal blood pressure \<120/70 mmHg
Secondary Outcomes
- Systolic blood pressure (mmHg) at 12 months(12 months)
- Medication adherence at 12 months(12 months)
- Diastolic blood pressure (mmHg) at 12 months(12 months)
